Retatrutide: What We Know So Far (2026 Update)

Retatrutide is a next-generation weight loss medication currently in Phase 3 clinical trials. Phase 2 data showed weight loss outcomes that exceed tirzepatide. Here's what the evidence shows, what's still unknown, and what the realistic timeline to availability looks like.

What Is Retatrutide?

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist developed by Eli Lilly, the same company behind tirzepatide. By adding glucagon receptor activation to the GLP-1 and GIP pathways that tirzepatide uses, retatrutide is designed to produce stronger metabolic and weight loss effects. Glucagon receptor activation increases energy expenditure and enhances fat burning.

Phase 2 Trial Results

The Phase 2 TRIUMPH trial published data showing:

Average weight loss of approximately 17.5% at 24 weeks (highest dose group)
Projected weight loss exceeding 24% at 48 weeks based on trajectory
Dose-dependent weight loss, higher doses produced stronger outcomes
Blood sugar improvements consistent with the GLP-1 mechanism

For context, tirzepatide produced approximately 20–22% weight loss over 72 weeks in SURMOUNT. If retatrutide's Phase 2 trajectory holds in Phase 3, it would represent the strongest weight loss medication approved to date.

Phase 3 Status

As of 2026, retatrutide is in Phase 3 trials. Phase 3 trials enroll significantly larger patient populations and are required before FDA approval. Phase 3 trials for weight loss medications typically run 52–72 weeks to capture outcomes data.

Eli Lilly has not announced a specific FDA submission timeline. A realistic estimate for potential FDA approval, assuming Phase 3 data supports efficacy and safety, would be 2027 at the earliest.

Important: As of 2026, retatrutide is not FDA-approved and is not available as a legitimate prescription medication for weight loss. Anyone offering retatrutide prescriptions through telehealth is misrepresenting the drug's regulatory status. This is not the same situation as compounded semaglutide or tirzepatide, which are approved medications being legally compounded.

Side Effect Profile

Phase 2 data showed a similar GI side effect profile to tirzepatide, nausea, vomiting, diarrhea, and constipation were the most common. The triple-agonist mechanism's glucagon component may produce additional effects; full characterization awaits Phase 3 data.

How It Compares to Current Options

Medication	Mechanism	Avg Weight Loss	Status
Semaglutide	GLP-1	~15%	FDA approved
Tirzepatide	GLP-1/GIP	~21%	FDA approved
Retatrutide	GLP-1/GIP/Glucagon	~24%+ (Phase 2)	Phase 3 trials

Frequently Asked Questions

Is retatrutide available as a prescription?

No. As of 2026, retatrutide is in Phase 3 clinical trials and has not received FDA approval. It is not available as a legitimate prescription medication for weight loss. Anyone offering retatrutide prescriptions through telehealth is misrepresenting the drug's regulatory status.

How does retatrutide compare to tirzepatide?

Phase 2 data shows retatrutide produced approximately 24% average weight loss vs tirzepatide's 20–22% in similar timeframes. The triple-agonist mechanism appears to produce stronger effects than tirzepatide's dual mechanism. Head-to-head Phase 3 comparison data is pending.

Medical Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. GLP-1 medications are prescription drugs that require evaluation by a licensed physician. Always consult a qualified healthcare provider before starting any medication. Individual results vary significantly.